Browse the evidence

Retatrutide may be superior to dulaglutide in reducing plasma glucose and body weight.

Practitioners may consider retatrutide as a potentially more effective option than dulaglutide for managing diabetes.

Reductions in visceral adiposity and estimated liver fat are associated with improvements in the ISI-Matsuda index over 3 years.

Targeting visceral fat reduction may enhance insulin sensitivity in interventions.

Both short (30 s) and long (150 s) rest intervals during low-load resistance training significantly increase growth hormone and insulin-like growth factor 1 immediately post-workout.

Practitioners can expect significant hormonal responses regardless of rest interval length in low-load training.

Semaglutide treatment resulted in a 17% reduction in new-onset atrial fibrillation (AF) incidence compared to controls.

Semaglutide may be an effective treatment option for reducing the risk of new-onset AF in patients.

In trials without SGLT2 inhibitors, there was a significant reduction of 21% in new-onset AF.

Semaglutide may be more effective in reducing AF risk when not used with SGLT2 inhibitors.

In most existing algorithms for calculating prandial insulin doses in type 1 diabetes, only carbohydrates are counted.

Current algorithms may need to be revised to include more than just carbohydrate counting.

In type 2 diabetes, the meal content is often not taken into consideration when calculating prandial insulin doses.

Practitioners should consider meal content when determining insulin doses for type 2 diabetes.

Both groups displayed a decrease in baseline resistin values after 16 weeks of resistance training.

Resistance training may help lower resistin levels, which could be beneficial for metabolic health.

Semaglutide is associated with cardiovascular risk reduction.

Practitioners can consider semaglutide as a potential option for reducing cardiovascular risk in adults.

The control session increased hunger scores (p < .01) and decreased circulating leptin levels (p = .03).

Inactivity may lead to increased hunger and decreased leptin in obese teenage girls.

Treatment of metabolic changes at menopause requires a flexible long-term strategy.

Practitioners should develop adaptable treatment plans for managing menopause-related metabolic changes.

Preoperative fasting plasma C-peptide was predictive of increased chance of remission of type 2 diabetes after bariatric surgery (pooled difference in means = 0.93, 95% CI = 0.61 to 1.25, p < .001).

Practitioners may consider preoperative fasting C-peptide levels as a significant predictor for diabetes remission post-surgery.

SGLT-2 inhibitors and GLP-1 receptor agonists are effective in cardiovascular disease prevention among those with diabetes, heart failure, and chronic kidney disease.

Healthcare providers should consider these agents for patients with diabetes and related cardiovascular conditions.

GLP1-RA therapy appears safe and effective in patients with IBD.

GLP1-RA may be considered a treatment option for managing IBD.

GLP-1 receptor agonists have beneficial effects on atherosclerosis and cardiovascular disease.

Practitioners may consider GLP-1 receptor agonists as a treatment option for improving cardiovascular health in patients with obesity and type 2 diabetes.

Insulin dynamics, such as insulin sensitivity or insulin secretion status, may interact with diets that vary in macronutrient composition.

Understanding insulin dynamics can help in designing more effective dietary interventions.

Insulin dynamics, such as insulin sensitivity or insulin secretion status, may interact with diets that vary in macronutrient composition.

Dietary recommendations may need to consider an individual's insulin dynamics.

Semaglutide reduced HbA1c by 0.46% of total hemoglobin in SGA-treated patients with schizophrenia, prediabetes, and obesity.

Semaglutide may be an effective treatment option for managing blood glucose levels in this patient population.

Semaglutide and tirzepatide show therapeutic potential as cardioprotective and nephroprotective agents.

Practitioners can consider semaglutide and tirzepatide for patients at risk of cardiovascular and renal diseases.

The GLP-1RA/GIPR antagonist MariTide achieved substantial reductions in weight and HbA1c.

MariTide may be an effective option for weight management and glycemic control in patients.

Current pharmacotherapy options for obesity include agents like liraglutide, semaglutide, and tirzepatide.

Practitioners should be aware of these specific pharmacotherapy options for treating obesity.

Novel therapies, including dual and triple incretin agonists, are under investigation for obesity treatment.

Practitioners should stay informed about emerging therapies that may enhance obesity treatment.

Certain metabolic and comorbid conditions disproportionately affect women.

Practitioners should consider gender-specific factors in obesity management.

Male participants experienced greater effects than females (P < 0.001).

Practitioners should consider gender differences when designing resistance training programs.